Drug Type Small molecule drug |
Synonyms (S)-(-)-alpha-Methyldopa, 3-Hydroxy-alpha-methyl-L-tyrosine, Alpha medopa + [23] |
Target |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (20 Dec 1962), |
RegulationOrphan Drug (US), Fast Track (US) |
Molecular FormulaC20H32N2O11 |
InChIKeyYKFCISHFRZHKHY-NGQGLHOPSA-N |
CAS Registry41372-08-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00405 | Methyldopa |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | US | 20 Dec 1962 | |
Hypertension | US | 20 Dec 1962 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinopathy of Prematurity | Phase 2 | US | - | |
Diabetes Mellitus, Type 1 | Phase 1 | US | 09 Nov 2020 |
Not Applicable | 54 | ACE inhibitors | vppjdsqekx(hzstqizzxy) = fyhljodwsr izpjdvhjph (cnawwnwvuf ) View more | Positive | 28 Aug 2020 | ||
vppjdsqekx(hzstqizzxy) = kjefcbspvu izpjdvhjph (cnawwnwvuf ) View more | |||||||
Not Applicable | 30 | kenwwfjlxk(wddpgsvyoe) = yhdrwdunmz navolypkmb (ttkmudhjmv, szxwzpgycn - vvcscrhmjv) View more | - | 29 Mar 2018 | |||
Not Applicable | Choroidal Neovascularization anti-VEGF antibody | 419 | pdluerozsq(eqbkgbdgzo) = httpvdmbdx bygpmwxyat (oretzztiyv ) | - | 01 Mar 2012 | ||
pdluerozsq(eqbkgbdgzo) = pvqnfkutyg bygpmwxyat (oretzztiyv ) |